読み込み中
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
前日終値
$19.94
−$0.03 · -0.15%
日中の時刻はETです。市場データは遅延する場合があります。
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
日中レンジ
現在 $19.94
52週レンジ
現在 $19.94
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
39
割高
センチメント
70
強気
リスク
48
やや高いリスク
モメンタム
65
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
日中レンジ
現在 $19.94
52週レンジ
現在 $19.94
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 1.03億 USD | 8007.7万 USD | 6251.8万 USD | 4300.8万 USD | 2063.6万 USD |
| 販売・一般管理 | 2983.4万 USD | 2410万 USD | 1742.7万 USD | 1591.9万 USD | 565.2万 USD |
| 営業費用 | 1.33億 USD | 1.04億 USD | 7994.5万 USD | 5892.7万 USD | 2628.8万 USD |
| 受取利息 | 1281.5万 USD | 1769.6万 USD | 1081.1万 USD | 365.2万 USD | 1.3万 USD |
| 減価償却費と償却費 | 54.6万 USD | 51.9万 USD | 35.7万 USD | 29.6万 USD | 14万 USD |
| 営業利益 | −1.33億 USD | −1.04億 USD | −7994.5万 USD | −5892.7万 USD | −2628.8万 USD |
| 純利益 | −1.2億 USD | −8648.1万 USD | −6913.4万 USD | −5532.5万 USD | −2629.4万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$45.17
上昇余地（126.53%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI2842.09万0.00%2.3兆 USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI2337.38万0.24%98.74億 USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM1942.62万0.02%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF862.97万0.01%954億 USD0.05%$235+0.80%
iShares Biotechnology ETFIBB816.99万0.08%108.2億 USD0.44%$206.49+3.00%
iShares Russell 2000 Growth ETFIWO675.51万0.05%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO529.18万0.03%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA465.32万0.02%218.24億 USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
